Regulatory Agencies Approve Aventis Sale Of Refludano to Schering AG
Aventis Pharmaceuticals, the U.S. pharmaceutical company of Aventis Pharma AG, today announced that the U.S. Federal Trade Commission (FTC) and the Commission of the European Communities have approved the sale of its prescription product RefludanÃ’ (lepirudin) to Schering AG of Berlin, Germany. The divestment of Refludan was required to satisfy conditions set by the FTC and the European Commission in late 1999 for their approval of the business combination of Hoechst AG and Rhone Poulenc SA, which became Aventis.
The deal involved an undisclosed cash payment by Schering to Aventis Pharma in exchange for complete worldwide rights to Refludan. Refludan is a genetically engineered hirudin and is indicated for the treatment of heparin-induced thrombocytopenia (HIT). Refludan received regulatory approval from the European Medicines Evaluation Agency in March of 1997, and from the U.S. Food & Drug Administration in March of 1998.
Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG. With headquarters in Bridgewater, N.J., Aventis Pharmaceuticals focuses its activities on important therapeutic areas such as cardiology, oncology, anti-infectives, arthritis, allergy and respiratory, diabetes, and the central nervous system.
Other news from the department business & finance
